| Literature DB >> 31689241 |
Joanna Mikulak1,2, Ferdinando Oriolo1,2, Elena Bruni1,2, Alessandra Roberto3, Federico S Colombo4, Anna Villa5,6, Marita Bosticardo5, Ileana Bortolomai5, Elena Lo Presti7,8, Serena Meraviglia7,8, Francesco Dieli7,8, Stefania Vetrano9,10, Silvio Danese9,10, Silvia Della Bella1,2, Michele M Carvello11, Matteo Sacchi11, Giovanni Cugini12, Giovanni Colombo12, Marco Klinger2,13, Paola Spaggiari14, Massimo Roncalli10,11,12,13,14, Immo Prinz15, Sarina Ravens15, Biagio di Lorenzo16,17, Emanuela Marcenaro18,19, Bruno Silva-Santos16, Antonino Spinelli10,11, Domenico Mavilio1,2.
Abstract
γδ T cells account for a large fraction of human intestinal intraepithelial lymphocytes (IELs) endowed with potent antitumor activities. However, little is known about their origin, phenotype, and clinical relevance in colorectal cancer (CRC). To determine γδ IEL gut specificity, homing, and functions, γδ T cells were purified from human healthy blood, lymph nodes, liver, skin, and intestine, either disease-free, affected by CRC, or generated from thymic precursors. The constitutive expression of NKp46 specifically identifies a subset of cytotoxic Vδ1 T cells representing the largest fraction of gut-resident IELs. The ontogeny and gut-tropism of NKp46+/Vδ1 IELs depends both on distinctive features of Vδ1 thymic precursors and gut-environmental factors. Either the constitutive presence of NKp46 on tissue-resident Vδ1 intestinal IELs or its induced expression on IL-2/IL-15-activated Vδ1 thymocytes are associated with antitumor functions. Higher frequencies of NKp46+/Vδ1 IELs in tumor-free specimens from CRC patients correlate with a lower risk of developing metastatic III/IV disease stages. Additionally, our in vitro settings reproducing CRC tumor microenvironment inhibited the expansion of NKp46+/Vδ1 cells from activated thymic precursors. These results parallel the very low frequencies of NKp46+/Vδ1 IELs able to infiltrate CRC, thus providing insights to either follow-up cancer progression or to develop adoptive cellular therapies.Entities:
Keywords: Colorectal cancer; Gastroenterology; Immunology; Innate immunity; T cells
Mesh:
Substances:
Year: 2019 PMID: 31689241 PMCID: PMC6975269 DOI: 10.1172/jci.insight.125884
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708